• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Maxcyte Inc (NQ: MXCT )

    3.735 +0.035 (+0.95%)
    Streaming Delayed Price Updated: 11:48 AM EDT, Oct 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Maxcyte Inc

    < Previous 1 2 3 4 5 Next >
    MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Earnings Preview
    Via Benzinga
    MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
    Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology 
    From MaxCyte, Inc
    Via GlobeNewswire
    MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024
    MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
    Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T... 
    From MaxCyte, Inc
    Via GlobeNewswire
    Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024
    MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
    Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs 
    From MaxCyte, Inc
    Via GlobeNewswire
    Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
    Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. 
    Via Benzinga
    Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    U.S. stock futures were slightly lower this morning, with the Dow futures falling by around 0.1% on Wednesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
    U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    Earnings Scheduled For March 12, 2024
    Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. 
    Via Benzinga
    MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
    Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers 
    From MaxCyte, Inc
    Via GlobeNewswire
    MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
    Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer... 
    From MaxCyte, Inc
    Via GlobeNewswire
    Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Cell Engineering Company MaxCyte Shares Are Up Today
    MaxCyte Inc (NASDAQ: MXCT) shares are trading higher by over 9% after the company disclosed strong preliminary Q4 and full-year  
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.